**Core Concept:** Rapid-acting insulin is a type of insulin analogue designed to mimic the physiological properties of human insulin, particularly its peak action and duration of action. It is commonly used in the management of type 1 and type 2 diabetes, particularly for improving postprandial blood glucose control.

**Why the Correct Answer is Right:** Glargine is a long-acting insulin analogue, also known as basal insulin, which is commonly used to manage type 1 and type 2 diabetes. It has a flat and sustained pharmacokinetic profile, meaning that it maintains a stable blood glucose-lowering effect throughout the day. However, it does not mimic the physiological properties of human insulin, such as peak action and duration of action.

**Why Each Wrong Option is Incorrect:**
A. Aspart and lispro are rapid-acting insulin analogues, which have a peak action within 15-30 minutes and a duration of action lasting 4-6 hours. These options are incorrect because they are not long-acting insulins.
B. Glargine is a long-acting insulin analogue, not a rapid-acting insulin. It maintains a stable blood glucose-lowering effect throughout the day but does not match the physiological action of human insulin.
C. Detemir is another long-acting insulin analogue with a peak action occurring after 2-4 hours and a duration of action lasting 20-26 hours. This option is incorrect because it is not a rapid-acting insulin.
D. Insulin glulisine is a rapid-acting insulin analogue, with a peak action occurring within 15-30 minutes and a duration of action lasting 4-6 hours. This option is incorrect because it is a rapid-acting insulin, not a long-acting insulin.

**Clinical Pearl:** Rapid-acting insulins, such as insulin aspart and insulin lispro, are commonly used in the management of type 1 and type 2 diabetes to mimic the physiological action of human insulin, ensuring better postprandial blood glucose control.

**Correct Answer:** D. Insulin glulisine is a rapid-acting insulin analogue, with a peak action occurring within 15-30 minutes and a duration of action lasting 4-6 hours. This option is correct because it is a rapid-acting insulin, not a long-acting insulin. Insulin glulisine is commonly used in combination with long-acting insulin, such as insulin glargine, to provide comprehensive blood glucose control.